343308-49-6

Upstream product

• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 109-64-8 1,3-dibromo-propane 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 343308-46-3 methyl 4-(3-bromopropoxy)-3-methoxybenzoate 

Downstream Products

• 1320288-23-0 methyl 5-methoxy-2-nitro-4-[3-(pyrrolidin-1-yl)propoxy]benzoate 
• 1320288-30-9 2,4-dichloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline 
• 1320288-29-6 6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-1H-quinazoline-2,4-dione 
• 760155-54-2 2-amino-5-methoxy-4-(3-pyrrolidin-1-ylpropoxy)benzamide 
• 199327-73-6 5-methoxy-2-nitro4-(3-(pyrrolidin-1-yl)propoxy)benzamide 
• 745776-25-4 5-methoxy-2-nitro-4-(3-pyrrolidin-1-ylpropoxy)benzoic acid 
• 574738-72-0 methyl 5-methoxy-4-(3-bromopropoxy)anthranilate 
• 478552-12-4 [(S)-2-(Bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-{5-methoxy-4-[3-(4-methyl-piperazin-1-yl)-propoxy]-2-nitro-phenyl}-methanone 
• 478552-18-0 {2-Amino-5-methoxy-4-[3-(4-methyl-piperazin-1-yl)-propoxy]-phenyl}-[(S)-2-(bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-methanone 
• 478552-10-2 [(S)-2-(Bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-[5-methoxy-4-(3-morpholin-4-yl-propoxy)-2-nitro-phenyl]-methanone 
• 478552-11-3 [2-Amino-5-methoxy-4-(3-morpholin-4-yl-propoxy)-phenyl]-[(S)-2-(bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-methanone 
• 478552-15-7 [(S)-2-(Bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-[4-(3-diethylamino-propoxy)-5-methoxy-2-nitro-phenyl]-methanone 
• 478552-19-1 [2-Amino-4-(3-diethylamino-propoxy)-5-methoxy-phenyl]-[(S)-2-(bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-methanone 
• 478552-07-7 (S)-1-[4-(3-Bromo-propoxy)-5-methoxy-2-nitro-benzoyl]-pyrrolidine-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Using knowledge- and structure-based approaches, we designed and synthesized reversible chemical probes that simultaneously inhibit the activity of two epigenetic targets, histone 3 lysine 9 methyltransferase (G9a) and DNA methyltransferases (DNMT), at nanomolar ranges. Enzymatic competition assays confirmed our design strategy: substrate competitive inhibitors. Next, an initial exploration around our hit 11 was pursued to identify an adequate tool compound for in vivo testing. In vitro treatment of different hematological neoplasia cell lines led to the identification of molecules with clear antiproliferative efficacies (GI50 values in the nanomolar range). On the basis of epigenetic functional cellular responses (levels of lysine 9 methylation and 5-methylcytosine), an acceptable therapeutic window (around 1 log unit) and a suitable pharmacokinetic profile, 12 was selected for in vivo proof-of-concept (Nat. Commun. 2017, 8, 15424). Herein, 12 achieved a significant in vivo efficacy: 70% overall tumor growth inhibition of a human acute myeloid leukemia (AML) xenograft in a mouse model.

Synthesis, DNA binding ability and anticancer activity of 2-heteroaryl substituted benzimidazoles linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates

As a continuation of our efforts to develop the benzimidazole-PBD conjugates as potential anticancer agents, a series of heteroaryl substituted benzimidazole linked PBD conjugates has been synthesized and evaluated for their anticancer potential in 60 human cancer cell lines. Most of the compounds exhibited promising anticancer activity and interestingly, compounds 4c and 4d displayed significant activity in most of the cell lines tested. Whereas, compound 4e showed selectivity in renal cancer cells with GI50 values of 10 and 70 nM against RXF 393 and UO-31 cell lines, respectively. Further, these compounds also showed significant DNA-binding affinity by thermal denaturation study using duplex form of calf thymus (CT) DNA.

DNA binding potential and cytotoxicity of newly designed pyrrolobenzodiazepine dimers linked through a piperazine side-armed-alkane spacer

New pyrrolobenzodiazepine (PBD) dimers have been developed that are composed of two DC-81 subunits tethered to their C8 positions through piperazine moiety side-armed with alkaneoxy linkers (composed of 2-5 carbons). DNA thermal denaturation studies show

PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE

A process for producing a quinazolin-4-one compound having the formula: [wherein R1, R2, R3 and R4 each represents a group not participating in the below-mentioned reaction, and R1, R2, R3 and R4 can be combined together to form a ring] which comprises reacting an anthranilic acid derivative having the formula: [wherein R5 is a hydrogen atom or a hydrocarbyl group] with a formic acid derivative in the presence of an ammonium carboxylate.

Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity

New sequence selective mixed imine-amide pyrrolobenzodiazepine (PBD) dimers have been developed that are comprised of DC-81 and dilactam of DC-81 subunits tethered to their C8 positions through alkanedioxy linkers (comprised of three to five and eight car

Synthesis of C-8 alkylamino substituted pyrrolo[2,1-c][1,4]benzodiazepines as potential anti-cancer agents

The design and facile synthesis of C-8 alkylamino substituted pyrrolo[2,1-c][1,4]benzodiazepines is described. These have been prepared by linking the amines at C-8 position with propane spacer to improve solubility in water, and their in vitro cytotoxici